{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:42:44Z","timestamp":1760316164636,"version":"build-2065373602"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,12]]},"DOI":"10.7759\/cureus.94396","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:24:08Z","timestamp":1760279048000},"source":"Crossref","is-referenced-by-count":0,"title":["Ophthalmology Considerations in End-of-Life Care"],"prefix":"10.7759","author":[{"given":"Mendel","family":"Shloush","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiva","family":"Eleff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Eleff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4065\/75.12.1305","article-title":"Maintaining quality of life at the end of life","volume":"75","author":"Rummans TA","year":"2000","unstructured":"Rummans TA, Bostwick JM, Clark MM. Maintaining quality of life at the end of life. Mayo Clin Proc. 2000, 75:1305-10. 10.4065\/75.12.1305","journal-title":"Mayo Clin Proc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/10499091211057849","article-title":"Harm versus burden","volume":"39","author":"Eleff A","year":"2022","unstructured":"Eleff A. Harm versus burden. Am J Hosp Palliat Care. 2022, 39:1266-7. 10.1177\/10499091211057849","journal-title":"Am J Hosp Palliat Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2016.0346","article-title":"Cataract surgery in hospice patients: pros, cons, and cost-effectiveness","volume":"19","author":"Nunn JG","year":"2016","unstructured":"Nunn JG, Shreve S, Scott IU, Pantanelli SM. Cataract surgery in hospice patients: pros, cons, and cost-effectiveness. J Palliat Med. 2016, 19:1245-6. 10.1089\/jpm.2016.0346","journal-title":"J Palliat Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4097\/kjae.2016.69.4.319","article-title":"Monitored anesthesia care in and outside the operating room","volume":"69","author":"Sohn HM","year":"2016","unstructured":"Sohn HM, Ryu JH. Monitored anesthesia care in and outside the operating room. Korean J Anesthesiol. 2016, 69:319-26. 10.4097\/kjae.2016.69.4.319","journal-title":"Korean J Anesthesiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein M","year":"2021","unstructured":"Fleckenstein M, Keenan TD, Guymer RH, et al.. Age-related macular degeneration. Nat Rev Dis Primers. 2021, 7:31. 10.1038\/s41572-021-00265-2","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault J","year":"2005","unstructured":"Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005, 46:726-33. 10.1167\/iovs.04-0601","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown DM","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, et al.. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1432-44. 10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.11.1532","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study","volume":"124","author":"Heier JS","year":"2006","unstructured":"Heier JS, Boyer DS, Ciulla TA, et al.. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006, 124:1532-42. 10.1001\/archopht.124.11.1532","journal-title":"Arch Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld PJ","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1419-31. 10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung AE","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, et al.. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007, 143:566-83. 10.1016\/j.ajo.2007.01.028","journal-title":"Am J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo CD","year":"2008","unstructured":"Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008, 145:239-48. 10.1016\/j.ajo.2007.10.004","journal-title":"Am J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth U","year":"2011","unstructured":"Schmidt-Erfurth U, Eldem B, Guymer R, et al.. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011, 118:831-9. 10.1016\/j.ophtha.2010.09.004","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: bevacizumab (Avastin\u00ae) plus Carboplatin and Paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen MH","year":"2007","unstructured":"Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin\u00ae) plus Carboplatin and Paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007, 12:713-8. 10.1634\/theoncologist.12-6-713","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12119","article-title":"Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks","volume":"91","author":"Lushchyk T","year":"2013","unstructured":"Lushchyk T, Amarakoon S, Martinez-Ciriano JP, van den Born LI, Baarsma GS, Missotten T. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks. Acta Ophthalmol. 2013, 91:e456-61. 10.1111\/aos.12119","journal-title":"Acta Ophthalmol"},{"key":"ref15","article-title":"Retinal detachment","author":"Blair K","year":"2025","unstructured":"Blair K, Czyz CN. Retinal detachment. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref16","article-title":"Retinal traction detachment","author":"Mishra C","year":"2025","unstructured":"Mishra C, Tripathy K. Retinal traction detachment. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6700194","article-title":"Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology","volume":"16","author":"Charteris DG","year":"2002","unstructured":"Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond). 2002, 16:369-74. 10.1038\/sj.eye.6700194","journal-title":"Eye (Lond)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200009000-00005","article-title":"Primary vitrectomy alone for repair of retinal detachments following cataract surgery","volume":"20","author":"Speicher MA","year":"2000","unstructured":"Speicher MA, Fu AD, Martin JP, von Fricken MA. Primary vitrectomy alone for repair of retinal detachments following cataract surgery. Retina. 2000, 20:459-64. 10.1097\/00006982-200009000-00005","journal-title":"Retina"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00292353","article-title":"Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?","volume":"234","author":"Duquesne N","year":"1996","unstructured":"Duquesne N, Bonnet M, Adeleine P. Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?. Graefes Arch Clin Exp Ophthalmol. 1996, 234:677-82. 10.1007\/BF00292353","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(92)31983-9","article-title":"Pseudophakic retinal detachments. Anatomic and visual results","volume":"76","author":"Greven CM","year":"1992","unstructured":"Greven CM, Sanders RJ, Brown GC, et al.. Pseudophakic retinal detachments. Anatomic and visual results. Ophthalmology. 1992, 76:257-62. 10.1016\/s0161-6420(92)31983-9","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199414050-00005","article-title":"Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery","volume":"14","author":"Girard P","year":"1994","unstructured":"Girard P, Mimoun G, Karpouzas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina. 1994, 14:417-24. 10.1097\/00006982-199414050-00005","journal-title":"Retina"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.77.4.199","article-title":"Pars plana vitrectomy for the treatment of rhegmatogenous retinal detachment uncomplicated by advanced proliferative vitreoretinopathy","volume":"77","author":"Gartry DS","year":"1993","unstructured":"Gartry DS, Chignell AH, Franks WA, Wong D. Pars plana vitrectomy for the treatment of rhegmatogenous retinal detachment uncomplicated by advanced proliferative vitreoretinopathy. Br J Ophthalmol. 1993, 77:199-203. 10.1136\/bjo.77.4.199","journal-title":"Br J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/BF00189354","article-title":"Cryopexy in primary rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?","volume":"234","author":"Bonnet M","year":"1996","unstructured":"Bonnet M, Fleury J, Guenoun S, Yaniali A, Dumas C, Hajjar C. Cryopexy in primary rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?. Graefes Arch Clin Exp Ophthalmol. 1996, 234:739-43. 10.1007\/BF00189354","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/BF00448800","article-title":"Primary vitrectomy without scleral buckling for rhegmatogenous retinal detachment","volume":"234","author":"Heimann H","year":"1996","unstructured":"Heimann H, Bornfeld N, Friedrichs W, Helbig H, Kellner U, Korra A, Foerster MH. Primary vitrectomy without scleral buckling for rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1996, 234:561-8. 10.1007\/BF00448800","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.10.022","article-title":"Primary Open-Angle Glaucoma Preferred Practice Pattern\u00ae","volume":"128","author":"Gedde SJ","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, et al.. Primary Open-Angle Glaucoma Preferred Practice Pattern\u00ae. Ophthalmology. 2021, 128:P71-150. 10.1016\/j.ophtha.2020.10.022","journal-title":"Ophthalmology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb RN","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014, 311:1901-11. 10.1001\/jama.2014.3192","journal-title":"JAMA"},{"key":"ref27","unstructured":"Glaucoma summary benchmarks - 2024. https.\/\/www.aao.org\/education\/summary-benchmark-detail\/glaucoma-summary-benchmarks-2020."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1130_17","article-title":"Simplifying \"target\" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma","volume":"66","author":"Sihota R","year":"2018","unstructured":"Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying \"target\" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018, 66:495-505. 10.4103\/ijo.IJO_1130_17","journal-title":"Indian J Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003919.pub3","article-title":"Laser trabeculoplasty for open-angle glaucoma and ocular hypertension","volume":"8","author":"Rolim-de-Moura CR","year":"2022","unstructured":"Rolim-de-Moura CR, Paranhos A Jr, Loutfi M, Burton D, Wormald R, Evans JR. Laser trabeculoplasty for open-angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2022, 8:CD003919. 10.1002\/14651858.CD003919.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","unstructured":"Reporting clinical endpoints in studies of minimally invasive glaucoma surgery - 2025. https.\/\/www.aao.org\/education\/clinical-statement\/reporting-clinical-endpoints-in-studies-of-minimal."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_3063_22","article-title":"Painful-blind eye: a forgotten palliative care","volume":"71","author":"Parra-Tanoux D","year":"2023","unstructured":"Parra-Tanoux D, Dussan-Vargas MP, Escandon MG. Painful-blind eye: a forgotten palliative care. Indian J Ophthalmol. 2023, 71:2399-408. 10.4103\/IJO.IJO_3063_22","journal-title":"Indian J Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001205","article-title":"Efficacy of care for blind painful eyes","volume":"35","author":"Idowu OO","year":"2019","unstructured":"Idowu OO, Ashraf DC, Kalin-Hajdu E, Ryan MC, Kersten RC, Vagefi MR. Efficacy of care for blind painful eyes. Ophthalmic Plast Reconstr Surg. 2019, 35:182-6. 10.1097\/IOP.0000000000001205","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000473","article-title":"Retrobulbar injections for blind painful eyes: a comparative study of retrobulbar alcohol versus chlorpromazine","volume":"25","author":"Galindo-Ferreiro A","year":"2016","unstructured":"Galindo-Ferreiro A, Akaishi P, Cruz A, et al.. Retrobulbar injections for blind painful eyes: a comparative study of retrobulbar alcohol versus chlorpromazine. J Glaucoma. 2016, 25:886-90. 10.1097\/IJG.0000000000000473","journal-title":"J Glaucoma"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200206000-00008","article-title":"Retrobulbar chlorpromazine injections for the management of blind and seeing painful eyes","volume":"11","author":"Chen TC","year":"2002","unstructured":"Chen TC, Ahn Yuen SJ, Sangalang MA, Fernando RE, Leuenberger EU. Retrobulbar chlorpromazine injections for the management of blind and seeing painful eyes. J Glaucoma. 2002, 11:209-13. 10.1097\/00061198-200206000-00008","journal-title":"J Glaucoma"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.V35N4p260","article-title":"Retrobulbar alcohol injection for orbital pain relief under difficult circumstances: a case report","volume":"35","author":"Kumar CM","year":"2006","unstructured":"Kumar CM, Dowd TC, Hawthorne M. Retrobulbar alcohol injection for orbital pain relief under difficult circumstances: a case report. Ann Acad Med Singap. 2006, 35:260-5. 10.47102\/annals-acadmedsg.V35N4p260","journal-title":"Ann Acad Med Singap"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000512","article-title":"Histologic evidence of orbital inflammation from retrobulbar alcohol and chlorpromazine injection: a clinicopathologic study in human & rat orbits","volume":"32","author":"Eftekhari K","year":"2016","unstructured":"Eftekhari K, Shindler KS, Lee V, Dine K, Eckstein LA, Vagefi MR. Histologic evidence of orbital inflammation from retrobulbar alcohol and chlorpromazine injection: a clinicopathologic study in human & rat orbits. Ophthalmic Plast Reconstr Surg. 2016, 32:302-4. 10.1097\/IOP.0000000000000512","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e318185365f","article-title":"Chronic orbital inflammation and fibrosis after retrobulbar alcohol and chlorpromazine injections in a patient with choroidal melanoma","volume":"24","author":"Cotliar JM","year":"2008","unstructured":"Cotliar JM, Shields CL, Meyer DR. Chronic orbital inflammation and fibrosis after retrobulbar alcohol and chlorpromazine injections in a patient with choroidal melanoma. Ophthalmic Plast Reconstr Surg. 2008, 24:410-1. 10.1097\/IOP.0b013e318185365f","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e3182a22c9f","article-title":"Orbital MRI appearance after remote retrobulbar alcohol injection","volume":"30","author":"Bialer OY","year":"2014","unstructured":"Bialer OY, Saindane AM, Newman NJ. Orbital MRI appearance after remote retrobulbar alcohol injection. Ophthalmic Plast Reconstr Surg. 2014, 30:e102-3. 10.1097\/IOP.0b013e3182a22c9f","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/01.iop.0000225419.09309.fc","article-title":"Periocular inflammation after retrobulbar chlorpromazine (thorazine) injection","volume":"22","author":"McCulley TJ","year":"2006","unstructured":"McCulley TJ, Kersten RC. Periocular inflammation after retrobulbar chlorpromazine (thorazine) injection. Ophthalmic Plast Reconstr Surg. 2006, 22:283-5. 10.1097\/01.iop.0000225419.09309.fc","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e31822dddc6","article-title":"Neurotrophic corneal ulcer after retrobulbar injection of chlorpromazine","volume":"28","author":"Hauck MJ","year":"2012","unstructured":"Hauck MJ, Lee HH, Timoney PJ, Shoshani Y, Nunery WR. Neurotrophic corneal ulcer after retrobulbar injection of chlorpromazine. Ophthalmic Plast Reconstr Surg. 2012, 28:e74-6. 10.1097\/IOP.0b013e31822dddc6","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.4.437","article-title":"Painful blind eye: efficacy of enucleation and evisceration in resolving ocular pain","volume":"84","author":"Shah-Desai SD","year":"2000","unstructured":"Shah-Desai SD, Tyers AG, Manners RM. Painful blind eye: efficacy of enucleation and evisceration in resolving ocular pain. Br J Ophthalmol. 2000, 84:437-8. 10.1136\/bjo.84.4.437","journal-title":"Br J Ophthalmol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708701","article-title":"Update on keratinocyte carcinomas","volume":"379","author":"Nehal KS","year":"2018","unstructured":"Nehal KS, Bichakjian CK. Update on keratinocyte carcinomas. N Engl J Med. 2018, 379:363-74. 10.1056\/NEJMra1708701","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00731-x","article-title":"Advances in topical treatments of cutaneous malignancies","volume":"24","author":"Algarin YA","year":"2023","unstructured":"Algarin YA, Jambusaria-Pahlajani A, Ruiz E, Patel VA. Advances in topical treatments of cutaneous malignancies. Am J Clin Dermatol. 2023, 24:69-80. 10.1007\/s40257-022-00731-x","journal-title":"Am J Clin Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14476","article-title":"Beyond Mohs surgery and excisions: a focused review of treatment options for subtypes of basal cell carcinoma","volume":"34","author":"Altun E","year":"2021","unstructured":"Altun E, Schwartzman G, Cartron AM, Khachemoune A. Beyond Mohs surgery and excisions: a focused review of treatment options for subtypes of basal cell carcinoma. Dermatol Ther. 2021, 34:e14476. 10.1111\/dth.14476","journal-title":"Dermatol Ther"},{"key":"ref45","article-title":"Basal cell and cutaneous squamous cell carcinomas: diagnosis and treatment","volume":"102","author":"Firnhaber JM","year":"2020","unstructured":"Firnhaber JM. Basal cell and cutaneous squamous cell carcinomas: diagnosis and treatment. Am Fam Physician. 2020, 102:339-46.","journal-title":"Am Fam Physician"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003412.pub3","article-title":"Interventions for basal cell carcinoma of the skin","volume":"11","author":"Thomson J","year":"2020","unstructured":"Thomson J, Hogan S, Leonardi-Bee J, Williams HC, Bath-Hextall FJ. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2020, 11:CD003412. 10.1002\/14651858.CD003412.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2023.10.011","article-title":"Periocular and ocular surface nonmelanoma skin cancer","volume":"42","author":"Hooper J","year":"2024","unstructured":"Hooper J, Shao K, Feng PW, Falcone M, Feng H. Periocular and ocular surface nonmelanoma skin cancer. Clin Dermatol. 2024, 42:71-7. 10.1016\/j.clindermatol.2023.10.011","journal-title":"Clin Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s1606","article-title":"Topical treatment options for conjunctival neoplasms","volume":"2","author":"Kim JW","year":"2008","unstructured":"Kim JW, Abramson DH. Topical treatment options for conjunctival neoplasms. Clin Ophthalmol. 2008, 2:503-15. 10.2147\/opth.s1606","journal-title":"Clin Ophthalmol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.02.021","article-title":"Palliative oncodermatology: management of malignancy-related cutaneous symptoms in the palliative care setting","volume":"92","author":"Oprea Y","year":"2025","unstructured":"Oprea Y, Deutsch A, McLellan B, Markova A. Palliative oncodermatology: management of malignancy-related cutaneous symptoms in the palliative care setting. J Am Acad Dermatol. 2025, 92:1351-9. 10.1016\/j.jaad.2025.02.021","journal-title":"J Am Acad Dermatol"},{"key":"ref50","unstructured":"Cornea\/external disease summary benchmarks - 2024. https.\/\/www.aao.org\/education\/summary-benchmark-detail\/cornea-external-disease-summary-benchmarks-2020."},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000659","article-title":"Ophthalmic procedures for treatment of advanced ocular surface diseases","volume":"92","author":"Bartlett AH","year":"2015","unstructured":"Bartlett AH, Bartlett JD. Ophthalmic procedures for treatment of advanced ocular surface diseases. Optom Vis Sci. 2015, 92:939-47. 10.1097\/OPX.0000000000000659","journal-title":"Optom Vis Sci"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.08.012","article-title":"Delphi-based global consensus on Fuchs endothelial corneal dystrophy. An Endothelial Keratoplasty Learners Group initiative","volume":"280","author":"Patel SV","year":"2025","unstructured":"Patel SV, Gupta N, Bhogal M, et al.. Delphi-based global consensus on Fuchs endothelial corneal dystrophy. An Endothelial Keratoplasty Learners Group initiative. Am J Ophthalmol. 2025, 280:130-43. 10.1016\/j.ajo.2025.08.012","journal-title":"Am J Ophthalmol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S83467","article-title":"Fuchs endothelial corneal dystrophy: current perspectives","volume":"10","author":"Vedana G","year":"2016","unstructured":"Vedana G, Villarreal G Jr, Jun AS. Fuchs endothelial corneal dystrophy: current perspectives. Clin Ophthalmol. 2016, 10:321-30. 10.2147\/OPTH.S83467","journal-title":"Clin Ophthalmol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2017-0081","article-title":"Evolving therapies for Fuchs' endothelial dystrophy","volume":"13","author":"Soh YQ","year":"2018","unstructured":"Soh YQ, Peh GS, Mehta JS. Evolving therapies for Fuchs' endothelial dystrophy. Regen Med. 2018, 13:97-115. 10.2217\/rme-2017-0081","journal-title":"Regen Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06129-7","article-title":"Emerging treatments for corneal endothelium decompensation \u2014 a systematic review","volume":"262","author":"Cheong N","year":"2024","unstructured":"Cheong N, Chui SW, Poon SH, Wong HL, Shih KC, Chan YK. Emerging treatments for corneal endothelium decompensation \u2014 a systematic review. Graefes Arch Clin Exp Ophthalmol. 2024, 262:381-93. 10.1007\/s00417-023-06129-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712770","article-title":"Injection of cultured cells with a ROCK inhibitor for bullous keratopathy","volume":"378","author":"Kinoshita S","year":"2018","unstructured":"Kinoshita S, Koizumi N, Ueno M, et al.. Injection of cultured cells with a ROCK inhibitor for bullous keratopathy. N Engl J Med. 2018, 378:995-1003. 10.1056\/NEJMoa1712770","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000062","article-title":"Alternatives to corneal transplantation for the management of bullous keratopathy","volume":"25","author":"Siu GD","year":"2014","unstructured":"Siu GD, Young AL, Jhanji V. Alternatives to corneal transplantation for the management of bullous keratopathy. Curr Opin Ophthalmol. 2014, 25:347-52. 10.1097\/ICU.0000000000000062","journal-title":"Curr Opin Ophthalmol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01839-6","article-title":"Cataracts","volume":"401","author":"Cataracts. Cicinelli MV","year":"2023","unstructured":"Cataracts. Cicinelli MV, Buchan JC, Nicholson M, Varadaraj V, Khanna RC. Cataracts. Lancet. 2023, 401:377-89. 10.1016\/S0140-6736(22)01839-6","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01660-5","article-title":"Treatment of non-infectious corneal injury: review of diagnostic agents, therapeutic medications, and future targets","volume":"82","author":"Dang DH","year":"2022","unstructured":"Dang DH, Riaz KM, Karamichos D. Treatment of non-infectious corneal injury: review of diagnostic agents, therapeutic medications, and future targets. Drugs. 2022, 82:145-67. 10.1007\/s40265-021-01660-5","journal-title":"Drugs"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.6.73","article-title":"Human platelet lysate treatment for exposure keratopathy: an in vivo confocal microscopy and anterior segment OCT study","volume":"66","author":"Tsai CY","year":"2025","unstructured":"Tsai CY, Huang WL, Yang SC, et al.. Human platelet lysate treatment for exposure keratopathy: an in vivo confocal microscopy and anterior segment OCT study. Invest Ophthalmol Vis Sci. 2025, 66:73. 10.1167\/iovs.66.6.73","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15676","article-title":"Impact of vision on generic health-related quality of life - a systematic review","volume":"101","author":"Purola P","year":"2023","unstructured":"Purola P, Koskinen S, Uusitalo H. Impact of vision on generic health-related quality of life - a systematic review. Acta Ophthalmol. 2023, 101:717-28. 10.1111\/aos.15676","journal-title":"Acta Ophthalmol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0661","article-title":"Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study","volume":"45","author":"Chia EM","year":"2004","unstructured":"Chia EM, Wang JJ, Rochtchina E, Smith W, Cumming RR, Mitchell P. Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci. 2004, 45:71-6. 10.1167\/iovs.03-0661","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-007-9280-7","article-title":"Visual impairment and quality of life: gender differences in the elderly in Cuenca, Spain","volume":"17","author":"Esteban JJ","year":"2008","unstructured":"Esteban JJ, Mart\u00ednez MS, Naval\u00f3n PG, Serrano OP, Pati\u00f1o JR, Pur\u00f3n ME, Mart\u00ednez-Vizca\u00edno V. Visual impairment and quality of life: gender differences in the elderly in Cuenca, Spain. Qual Life Res. 2008, 17:37-45. 10.1007\/s11136-007-9280-7","journal-title":"Qual Life Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0020","article-title":"Impact of impaired vision and eye disease on quality of life in Andhra Pradesh","volume":"47","author":"Nutheti R","year":"2006","unstructured":"Nutheti R, Shamanna BR, Nirmalan PK, Keeffe JE, Krishnaiah S, Rao GN, Thomas R. Impact of impaired vision and eye disease on quality of life in Andhra Pradesh. Invest Ophthalmol Vis Sci. 2006, 47:4742-8. 10.1167\/iovs.06-0020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-021-02817-1","article-title":"Prevalence and 11-year incidence of common eye diseases and their relation to health-related quality of life, mental health, and visual impairment","volume":"30","author":"Purola PK","year":"2021","unstructured":"Purola PK, N\u00e4ttinen JE, Ojamo MU, Koskinen SV, Rissanen HA, Sainio PR, Uusitalo HM. Prevalence and 11-year incidence of common eye diseases and their relation to health-related quality of life, mental health, and visual impairment. Qual Life Res. 2021, 30:2311-27. 10.1007\/s11136-021-02817-1","journal-title":"Qual Life Res"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02260-3","article-title":"Low vision status and declining vision decrease health-related quality of life: results from a nationwide 11-year follow-up study","volume":"28","author":"Taipale J","year":"2019","unstructured":"Taipale J, Mikhailova A, Ojamo M, et al.. Low vision status and declining vision decrease health-related quality of life: results from a nationwide 11-year follow-up study. Qual Life Res. 2019, 28:3225-36. 10.1007\/s11136-019-02260-3","journal-title":"Qual Life Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/393808-ophthalmology-considerations-in-end-of-life-care","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:24:14Z","timestamp":1760279054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/393808-ophthalmology-considerations-in-end-of-life-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,12]]},"references-count":66,"URL":"https:\/\/doi.org\/10.7759\/cureus.94396","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,12]]}}}